Irinotecan in the treatment of glioma patients : Current and future studies of the North Central Cancer Treatment Group (pages 2352–2358)
Jan C. Buckner, Joel M. Reid, Keith Wright, Scott H. Kaufmann, Charles Erlichman, Matthew Ames, Steve Cha, Judith R. O'Fallon, Lawrence J. Schaaf and Langdon L. Miller
Version of Record online: 17 APR 2003 | DOI: 10.1002/cncr.11304
Patients with newly diagnosed, high-grade astrocytoma or recurrent glioma rarely are treated successfully with currently available pharmaceutical agents. For those patients with high-grade glioma, the median survival from the time of diagnosis does not appear to have improved since the late 1970s. Irinotecan appears to have promise in the treatment of glioma patients based on in vitro and in vivo preclinical models.